ACE2 News and Research

RSS

What happens in the first few days of SARS-CoV-2 infection?

New research, published in PLOS Biology, has evaluated SARS-CoV-2 infection in primary cultures of well-differentiated cells to determine how the virus affects the body and how the infection starts. Answers to these questions are essential to forming a general understanding of viral pathogenesis, which helps us develop effective prevention and treatment strategies for COVID-19.

4 May 2021

Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

The study, published in the journal Circulation Research, suggests that COVID-19 is not only a respiratory disease but also a vascular disease. It highlights how the virus attacks the vascular system, causing endothelial impairment.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

The literature analysis pointed to elevated blood glucose levels as a leading facilitator in the progression of COVID-19. Evidence linking elevated glucose to various steps in the life cycle of the virus and presentation of COVID-19 symptoms were also found.

3 May 2021

SARS-CoV-2 study in human gut organoids

Most of the major life-threatening symptoms of COVID-19 disease are associated with the host's generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease.

3 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

SARS-CoV-2 spike mutations during transmission among humans and to animals

A fascinating new study discusses the 40 mutations that are seen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and their potential effects on viral biology.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

Scientists have known for a while that SARS-CoV-2's distinctive "spike" proteins help the virus infect its host by latching on to healthy cells. Now, a major new study shows that they also play a key role in the disease itself.

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.

2 May 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Furin cleavage site crucial in SARS-CoV-2 for viral transmission in ferrets, finds study

Researchers based at Imperial College London, UK, have recently highlighted the effects of these deleterious CS mutations through a ferret animal model, demonstrating that furin cleavage sites are a necessary component in the virus’ ability to replicate.

30 Apr 2021

Human to animal transmission of SARS-CoV-2 in households is common

Coronaviruses are seen in multiple mammalian species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, is said to have passed to humans from a mammalian source and to have originated from an animal reservoir as a zoonotic pathogen.

29 Apr 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Researchers in the United States have provided important insights into the pathophysiology of diarrhea that occurs in some cases of coronavirus disease 2019 (COVID-19).

29 Apr 2021

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.

29 Apr 2021

Host protein mimicry of SARS-CoV-2 receptor binding motif

In a new study, structural bioinformatics approaches are employed to investigate the potential mimicry of the receptor-binding motif (RBM) of these three coronaviruses, finding that several proteins from both human and non-human sources were similar to each, with implications regarding the mechanism of infection and tropism of SARS-CoV-2.

29 Apr 2021

ACE2 News and Research

What happens in the first few days of SARS-CoV-2 infection?

Can SARS-CoV-2’s impairment of endothelium cause vascular disease?

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19

SARS-CoV-2 study in human gut organoids

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

SARS-CoV-2 spike mutations during transmission among humans and to animals

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

SARS-CoV-2’s distinctive "spike" protein plays a key role in the disease itself, shows study

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Applications of nanoparticles in combating COVID-19

Furin cleavage site crucial in SARS-CoV-2 for viral transmission in ferrets, finds study

Human to animal transmission of SARS-CoV-2 in households is common

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

Host protein mimicry of SARS-CoV-2 receptor binding motif

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News